I’d like to have my genome sequenced. Can this be done at the Garvan Institute?
The Garvan Institute and the Kinghorn Centre for Clinical Genomics do not offer genome sequencing directly to consumers. Our clinical sequencing services are offered through Genome.One, a wholly-owned subsidiary of Garvan. Genome.One’s whole genome sequencing (WGS) tests must be requested by a medical specialist. If you are interested in having your genome sequenced for medical purposes, please discuss this with your family doctor and/or specialist.
If Garvan can’t sequence me, can you suggest someone who can?
The Garvan Institute does not endorse or recommend commercial products, processes or services. There are a number of commercial companies worldwide who offer medical genomic sequencing. These companies, in general, require authorisation from a qualified health professional but some offer direct-to-consumer testing.
If you are curious about genome sequencing and/or interested in the genetic tests currently available, you can find useful information on the NHMRC pages on genetics and genomics.
What does genome sequencing cost?
The cost of clinical sequencing through Genome.One varies. Please see the Genome.One website and consult your medical specialist for details.
The Kinghorn Centre for Clinical Genomics is currently offering research sequencing for ethically approved projects. Research project participants are not charged for genome sequencing.
Are there any plans for funding genomic testing through Medicare?
In short: not yet.
New genomics technologies such as whole exome or genome sequencing offer the potential to provide diagnosis and change the management of conditions with a genetic basis. However, effective use of new technologies requires a cohesive national collaborative approach to integrate the technology into clinical practice.
The Australian Genomic Healthcare Alliance (AGHA) is a collaboration involving Australia’s major medical research institutes, hospitals, state health departments and pathology and genetic services laboratories. It brings together a leading multidisciplinary team of biologists, physicians, geneticists, counsellors, bioinformaticians and public health experts at the forefront of genomic medicine, cancer and rare disease research, diagnosis and treatment internationally.
A working group from the AGHA is considering a national approach for a proposal to fund genomic testing for appropriate conditions through Medicare. While we believe this is the future for funding of genomic testing, this process is in its infancy. The submission will be informed by a thorough investigation of the clinical benefit of genomic testing, a health economic analysis and expert input from members of the AGHA and other relevant stakeholders.